N-truncation and pyroglutaminylation enhances the opsonizing capacity of Aβ-peptides and facilitates phagocytosis by macrophages and microglia

Brain, Behavior, and Immunity

Volumn 41, Issue 1, 2014, Pages 116-125

  Condic, Mateja ^a   Oberstein, Timo Jan ^a   Herrmann, Martin ^a   Reimann, Mareike Carola ^a   Kornhuber, Johannes ^a   Maler, Juan Manuel ^a   Spitzer, Philipp ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Amyloid precursor protein; A peptides; Macrophage; Macrophage polarization; Monocyte; Neuroinflammation; Opsonization; Phagocytosis

Indexed keywords

AMYLOID BETA PROTEIN; COLONY STIMULATING FACTOR 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; POLYSTYRENE; AMYLOID BETA-PROTEIN (3-42), PYROGLUTAMYL(3)-; IL10 PROTEIN, HUMAN; INDUCIBLE NITRIC OXIDE SYNTHASE; MICROSPHERE; NOS2 PROTEIN, HUMAN; OPSONIN; PEPTIDE FRAGMENT; PYROGLUTAMIC ACID;

ANIMAL CELL; ARTICLE; CELL PHAGOCYTOSIS; CONTROLLED STUDY; CYTOKINE RELEASE; ESCHERICHIA COLI; HUMAN; HUMAN CELL; INCUBATION TIME; MACROPHAGE; MICROGLIA; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OPSONIZATION; POLARIZATION; PRIORITY JOURNAL; ANIMAL; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECTS; IMMUNOLOGY; MACROPHAGE ACTIVATION; METABOLISM; PHAGOCYTOSIS; PHYSIOLOGY; PIG; PROTEIN PROCESSING; PROTEIN TERTIARY STRUCTURE; SECRETION (PROCESS); STRUCTURE ACTIVITY RELATION;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE; ESCHERICHIA COLI; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-10; MACROPHAGE ACTIVATION; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MICROGLIA; MICROSPHERES; MONOCYTES; NITRIC OXIDE SYNTHASE TYPE II; OPSONIN PROTEINS; PEPTIDE FRAGMENTS; PHAGOCYTOSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; PYRROLIDONECARBOXYLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; SUS SCROFA; SWINE;

EID: 84924058267     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2014.05.003     Document Type: Article

References (76)

1. Absolom D.R. The role of bacterial hydrophobicity in infection: bacterial adhesion and phagocytic ingestion. Can. J. Microbiol. 1988, 34(3):287-298.
2. Alexandru A., Jagla W., et al. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Abeta is induced by pyroglutamate-Abeta formation. J. Neurosci. 2011, 31(36):12790-12801.
3. Becker A., Kohlmann S., et al. Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration. BMC Neurosci. 2013, 14:108.
4. Bien J., Jefferson T., et al. The metalloprotease meprin beta generates amino terminal-truncated amyloid beta peptide species. J. Biol. Chem. 2012, 287(40):33304-33313.
5. Bitting L., Naidu A., et al. Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide. J Biol. Chem. 1996, 271(27):16084-16089.
6. Canton J., Neculai D., et al. Scavenger receptors in homeostasis and immunity. Nat. Rev. Immunol. 2013, 13(9):621-634.
7. Cashman J.R., Ghirmai S., et al. Immune defects in Alzheimer's disease: new medications development. BMC Neurosci. 2008, 9(Suppl. 2):S13.
8. Choucair-Jaafar N., Laporte V., et al. Complement receptor 3 (CD11b/CD18) is implicated in the elimination of beta-amyloid peptides. Fundam. Clin. Pharmacol. 2011, 25(1):115-122.
9. Cirrito J.R., Yamada K.A., et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005, 48(6):913-922.
10. Colton C.A., Mott R.T., et al. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflamm. 2006, 3:27.
11. Crisman J.M., Zhang B., et al. Deletion of the mouse meprin beta metalloprotease gene diminishes the ability of leukocytes to disseminate through extracellular matrix. J. Immunol. (Baltimore, Md: 1950) 2004, 172(7):4510-4519.
12. De Strooper B., Iwatsubo T., et al. Presenilins and gamma-secretase: structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect. Med. 2012, 2(1):a006304.
13. Dunn N., Mullee M., et al. Association between dementia and infectious disease: evidence from a case-control study. Alzheimer Dis. Assoc. Disord. 2005, 19(2):91-94.
14. Eikelenboom P., Veerhuis R., et al. The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr. Alzheimer Res. 2011, 8(2):142-150.
15. Eikelenboom P., van Exel E., et al. Innate immunity and the etiology of late-onset Alzheimer's disease. Neurodegener. Dis. 2012, 10(1-4):271-273.
16. Fiala M., Cribbs D.H., et al. Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J. Alzheimers Dis. 2007, 11(4):457-463.
17. Franke H., Galla H., et al. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res. Brain Res. Protoc. 2000, 5(3):248-256.
18. Fricker M., Oliva-Martin M.J., et al. Primary phagocytosis of viable neurons by microglia activated with LPS or Abeta is dependent on calreticulin/LRP phagocytic signalling. J. Neuroinflamm. 2012, 9:196.
19. Guntert A., Dobeli H., et al. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006, 143(2):461-475.
20. Hjorth E., Zhu M., et al. Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-beta42 by human microglia and decrease inflammatory markers. J. Alzheimers Dis. 2013, 35(4):697-713.
21. Honjo K., van Reekum R., et al. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease?. Alzheimers Dement. 2009, 5(4):348-360.
22. Jadidi-Niaragh F., Shegarfi H., et al. The role of natural killer cells in Alzheimer's disease. Scand. J. Immunol. 2012, 76(5):451-456.
23. Jung S.S., Gauthier S., et al. Beta-amyloid precursor protein is detectable on monocytes and is increased in Alzheimer's disease. Neurobiol. Aging 1999, 20(3):249-257.
24. Kaneider N.C., Lindner J., et al. The immune modulator FTY720 targets sphingosine-kinase-dependent migration of human monocytes in response to amyloid beta-protein and its precursor. FASEB J. 2004, 18(11):1309-1311.
25. Kang J.E., Cirrito J.R., et al. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity. Proc. Nat. Acad. Sci. U.S.A. 2007, 104(25):10673-10678.
26. Kopec K.K., Carroll R.T. Alzheimer's beta-amyloid peptide 1-42 induces a phagocytic response in murine microglia. J. Neurochem. 1998, 71(5):2123-2131.
27. Krut J.J., Zetterberg H., et al. Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections. J. Neurol. 2013, 260(2):620-626.
28. Ledoux S., Rebai N., et al. Amyloid precursor protein in peripheral mononuclear cells is up-regulated with cell activation. J. Immunol. (Baltimore, Md: 1950) 1993, 150(12):5566-5575.
29. Lewczuk P., Kornhuber J., et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: a multicenter study with multiplexing. Exp. Neurol. 2009.
30. Lewczuk P., Kornhuber J., et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol. Aging 2008, 29(6):812-818.
31. Malavolta M., Basso A., et al. Peripheral mononuclear cell rejuvenation for senescence surveillance in Alzheimer disease. Curr. Pharm. Des. 2013, 19(9):1720-1726.
32. Maler J.M., Klafki H.-W., et al. Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics 2007, 7(20):3815-3820.
33. Maler J.M., Spitzer P., et al. Adherence-dependent shifts in the patterns of beta-amyloid peptides secreted by human mononuclear phagocytes. Brain Behav. Immun. 2008, 22(7):1044-1048.
34. Maler J.M., Spitzer P., et al. Distinct fractional Abeta release patterns in human mononuclear phagocytes. J. Neuroimmunol. 2009, 206(1-2):1-4.
35. Mantovani A., Sica A., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25(12):677-686.
36. Mattsson N., Axelsson M., et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult. Scler. 2009, 15(4):448-454.
37. Mattsson N., Bremell D., et al. Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol. 2010, 10:51.
38. Mattsson N., Rajendran L., et al. BACE1 inhibition induces a specific cerebrospinal fluid beta-amyloid pattern that identifies drug effects in the central nervous system. PLoS One 2012, 7(2):e31084.
39. Meral D., Urbanc B. Discrete molecular dynamics study of oligomer formation by N-terminally truncated amyloid beta-protein. J. Mol. Biol. 2013, 425(12):2260-2275.
40. Michelucci A., Heurtaux T., et al. Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J. Neuroimmunol. 2009, 210(1-2):3-12.
41. Monning U., Konig G., et al. Synthesis and secretion of Alzheimer amyloid beta A4 precursor protein by stimulated human peripheral blood leucocytes. FEBS Lett. 1990, 277(1-2):261-266.
42. Monsonego A., Nemirovsky A., et al. CD4 T cells in immunity and immunotherapy of Alzheimer's disease. Immunology 2013, 139(4):438-446.
43. Nakano K., Nomura R., et al. Protein antigen in serotype k Streptococcus mutans clinical isolates. J. Dent. Res. 2008, 87(10):964-968.
44. Neniskyte U., Brown G.C. Lactadherin/MFG-E8 is essential for microglia-mediated neuronal loss and phagoptosis induced by amyloid beta. J. Neurochem. 2013, 126(3):312-317.
45. Pan X.D., Zhu Y.G., et al. Microglial phagocytosis induced by fibrillar beta-amyloid is attenuated by oligomeric beta-amyloid: implications for Alzheimer's disease. Mol. Neurodegener. 2011, 6:45.
46. Pike C.J., Overman M.J., et al. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J. Biol. Chem. 1995, 270(41):23895-23898.
47. Portelius E., Bogdanovic N., et al. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease. Acta Neuropathol. 2010, 120(2):185-193.
48. Portelius E., Price E., et al. A novel pathway for amyloid precursor protein processing. Neurobiol. Aging 2011, 32(6):1090-1098.
49. Richartz E., Batra A., et al. Diminished production of proinflammatory cytokines in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2005, 19(4):184-188.
50. Rojo L.E., Fernandez J.A., et al. Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease. Arch. Med. Res. 2008, 39(1):1-16.
51. Salminen A., Ojala J., et al. Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 2009, 87(3):181-194.
52. Schilling S., Lauber T., et al. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 2006, 45(41):12393-12399.
53. Schlenzig D., Manhart S., et al. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 2009, 48(29):7072-7078.
54. Selkoe D.J. Alzheimer's disease. Cold Spring Harb Perspect. Biol. 2011, 3(7).
55. Seong S.Y., Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 2004, 4(6):469-478.
56. Sevalle J., Amoyel A., et al. Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide. J. Neurochem. 2009, 109(1):248-256.
57. Sjogren M., Gisslen M., et al. Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci. Lett. 2001, 314(1-2):33-36.
58. Solerte S.B., Cravello L., et al. Overproduction of IFN-gamma and TNF-alpha from natural killer (NK) cells is associated with abnormal NK reactivity and cognitive derangement in Alzheimer's disease. Ann. N. Y. Acad. Sci. 2000, 917:331-340.
59. Sondag C.M., Combs C.K. Amyloid precursor protein mediates proinflammatory activation of monocytic lineage cells. J. Biol. Chem. 2004, 279(14):14456-14463.
60. Speciale L., Calabrese E., et al. Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients. Neurobiol. Aging 2007, 28(8):1163-1169.
61. Spies P.E., Verbeek M.M., et al. Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease. Front. Biosci. (Landmark Ed) 2012, 17:2024-2034.
62. Spitzer P., Herrmann M., et al. Phagocytosis and LPS alter the maturation state of b-amyloid precursor protein and induce different Ab peptide release signatures in human mononuclear phagocytes. J. Neuroinflamm. 2010, 7:59.
63. Sudduth T.L., Schmitt F.A., et al. Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol. Aging 2013, 34(4):1051-1059.
64. Sun Q., Jin H.J., et al. Disruption of the meprin alpha and beta genes in mice alters homeostasis of monocytes and natural killer cells. Exp. Hematol. 2009, 37(3):346-356.
65. Swardfager W., Lanctot K., et al. A meta-analysis of cytokines in Alzheimer's disease. Biol. Psychiatry 2010, 68(10):930-941.
66. Takeda K., Araki W., et al. Amino-truncated amyloid beta-peptide (Abeta5-40/42) produced from caspase-cleaved amyloid precursor protein is deposited in Alzheimer's disease brain. FASEB J. 2004, 18(14):1755-1757.
67. Tiffany H.L., Lavigne M.C., et al. Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. J. Biol. Chem. 2001, 276(26):23645-23652.
68. Town T., Nikolic V., et al. The microglial "activation" continuum: from innate to adaptive responses. J. Neuroinflamm. 2005, 2:24.
69. Tsitsopoulos P.P., Marklund N. Amyloid-beta peptides and tau protein as biomarkers in cerebrospinal and interstitial fluid following traumatic brain injury: a review of experimental and clinical studies. Front. Neurol. 2013, 4:79.
70. Tsuda H., Yamashita Y., et al. Role of serotype-specific polysaccharide in the resistance of Streptococcus mutans to phagocytosis by human polymorphonuclear leukocytes. Infect. Immun. 2000, 68(2):644-650.
71. Varnum M.M., Ikezu T. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch. Immunol. Ther. Exp. (Warsz) 2012, 60(4):251-266.
72. Wirths O., Breyhan H., et al. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009, 118(4):487-496.
73. Wittnam J.L., Portelius E., et al. Pyroglutamate amyloid beta (Abeta) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J. Biol. Chem. 2012, 287(11):8154-8162.
74. Xue J., Schmidt S.V., et al. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity 2014, 40(2):274-288.
75. Yamamoto M., Kiyota T., et al. Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J. Immunol. (Baltimore, Md: 1950) 2008, 181(6):3877-3886.
76. Zhang H., Su Y.J., et al. Activated scavenger receptor a promotes glial internalization of abeta. PLoS One 2014, 9(4):e94197.